.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX11_Tasonermin.Tasonermin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX11_Tasonermin.Tasonermin| name: | Tasonermin | |
| ATC code: | L03AX11 | |
| route: | intraarterial | |
| compartments: | 2 | |
| dosage: | 3 | mg |
| volume of distribution: | 3 | L |
| clearance: | 19.4 | L/h |
| other parameters in model implementation | ||
Tasonermin (also known as tumor necrosis factor alpha-1, TNF-alpha-1, or Beromun) is a recombinant form of human tumor necrosis factor alpha (TNF-α). It is an antineoplastic agent used in the treatment of certain advanced soft tissue sarcomas of the limbs. Tasonermin is administered via isolated limb perfusion to maximize local anti-tumoral effects and minimize systemic toxicity. Its use is rare and restricted to specific clinical scenarios, and it is not widely approved or used today outside select specialized indications.
Pharmacokinetic parameters of tasonermin in adult patients with soft tissue sarcoma undergoing isolated limb perfusion, as reported by clinical trials and regulatory assessments.